FREEHOLD, N.J., June 13, 2019 /PRNewswire/ -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of cell-based technologies and therapeutics, announced today the Company's President and Chief Executive Officer, David Jin. M.D., Ph.D., will participate at the Second International Aesthetic Industry Conference in Chengdu, China, the largest scale of its kind across all of Asia.

Dr. Jin will lead the "Application of Stem Cell Exosomes" session, acting as both chair and speaker of the panel. At this time, Dr. Jin will also unveil the launch of Avalon's new exosome product commercialization plan. The company will be providing a series of skincare and wound-healing products with Avalon's Clinical-grade Tissue-specific EXosomes as additives (ACTEX). 

Additionally, Yu Zhou, the Co-CEO of Avalon's subsidiary GenExosome Technologies, will provide the conference keynote address.   GenExosome Technologies developed the proprietary exosome isolation systems in order to promote implementation of exosome biotechnology in "liquid biopsies" and provide innovative exosome products for clinical diagnosis and treatment. Yu Zhou's keynote presentation is titled "Application of Exosome Technology in Aesthetic Industry: Isolation, Quality Control, and Exosomic Analysis."  

"Avalon GloboCare is dedicated to assembling and integrating the premier scientific, clinical, and regulatory resources from around the world, in order to accelerate innovative and transformative cellular and exosome-based technologies, as well as their clinical applications," stated Dr. Jin. "We are honored to lead a panel with international experts to discuss this evolving ecosystem, as well as showcasing our exosome product commercialization plan."

For more information on the conference, please see below:
Session Information:
Date: June 15, 2019
Time: 3:30 pm – 6:30 pm
Venue: Century City New International Convention and Exhibition Center, Chengdu, China

About Avalon GloboCare Corp.

Avalon GloboCare Corp. (NASDAQ: AVCO) is a leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative exosome technologies and cellular therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth, development, as well as competitiveness in both the domestic and global healthcare markets. Through its subsidiaries, namely GenExosome Technologies Inc. and Avactis Biosciences Inc., Avalon is establishing a leading role in the fields of exosome-based diagnostics (''liquid biopsy''), cellular immunotherapy (including CAR-T/CAR-NK), and regenerative medicine.

Forward-Looking Statements

Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.

SOURCE Avalon GloboCare Corp.